DXCM — DexCom, Inc.
$77.94-0.49%
Last close: · regular session
Last 60 sessions
DXCM closed at $77.94 (-0.49%) on Oct 23, 2026. Float: 375.9M shares. Latest SEC filing: 8-K on Jul 30, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for DXCM in the TickerWise workspace.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Company profile
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
- Exchange: NASDAQ
- Employees: 10,200
- Website: https://www.dexcom.com
Latest SEC filings for DXCM
Latest DXCM news
- DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study Read article
- DexCom gains as NEJM publication boosts Medicare coverage hopes Read article
- Here's Why You Should Retain DexCom Stock in Your Portfolio for Now Read article
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading Read article
- DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care Read article
- Here's Why DexCom (DXCM) is a Strong Growth Stock Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.